Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 190

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Open access
Moskowitz, Alison J., Ghione, Paola, Jacobsen, Eric, Ruan, Jia, Schatz, Jonathan H., Noor, Sarah, Myskowski, Patricia, Vardhana, Santosha, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Ryu, Sunyoung, Santarosa, Alayna, Dowd, Jack, Obadi, Obadi, Pomerantz, Lauren, Yi, Nancy, Sohail, Samia, Galasso, Natasha, Neuman, Rachel, Liotta, Brielle, Blouin, William, Baik, Jeeyeon, Geyer, Mark B., Noy, Ariela, Straus, David, Kumar, Priyadarshini, Dogan, Ahmet, Hollmann, Travis, Drill, Esther, Rademaker, Jurgen, Schoder, Heiko, Inghirami, Giorgio, Weinstock, David M., Horwitz, Steven M. · 2021 · Blood

Abstract

Signaling through JAK1 and/or JAK2 is common among tumor and nontumor cells within peripheral T-cell lymphoma (PTCL). No oral therapies are approved for PTCL, and better treatments for relapsed/refractory disease are urgently needed. We conducted a phase 2 study of the JAK1/2 inhibitor ruxolitinib for patients with relapsed/refractory PTCL (n = 45) or mycosis fungoides (MF) (n = 7). Patients enrolled onto 1 of 3 biomarker-defined cohorts: (1) activating JAK and/or STAT mutations, (2) ≥30% pSTAT3 expression among tumor cells by immunohistochemistry, or (3) neither or insufficient tissue to assess. Patients received ruxolitinib 20 mg PO twice daily until progression and were assessed for response after cycles 2 and 5 and every 3 cycles thereafter. The primary endpoint was clinical benefit rate (CBR), defined as the combination of complete response, partial response (PR), and stable disease lasting at least 6 months. Only 1 of 7 patients with MF had CBR (ongoing PR > 18 months). CBR among the PTCL cases (n = 45) in cohorts 1, 2, and 3 were 53%, 45%, and 13% (cohorts 1 & 2 vs 3, P = .02), respectively. Eight patients had CBR > 12 months (5 ongoing), including 4 of 5 patients with T-cell large granular lymphocytic leukemia. In an exploratory analysis using multiplex immunofluorescence, expression of phosphorylated S6, a marker of PI3 kinase or mitogen-activated protein kinase activation, in <25% of tumor cells was associated with response to ruxolitinib (P = .05). Our findings indicate that ruxolitinib is active across various PTCL subtypes and support a precision therapy approach to JAK/STAT inhibition in patients with PTCL. This trial was registered at www.clincialtrials.gov as #NCT02974647.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021013379

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 190

Metadata

Authors
Moskowitz, A. J., Ghione, P., Jacobsen, E., Ruan, J., Schatz, J. H., Noor, S., Myskowski, P., Vardhana, S., Ganesan, N., Hancock, H., Davey, T., Perez, L., Ryu, S., Santarosa, A., Dowd, J., Obadi, O., Pomerantz, L., Yi, N., Sohail, S., Galasso, N., Neuman, R., Liotta, B., Blouin, W., Baik, J., Geyer, M. B., Noy, A., Straus, D., Kumar, P., Dogan, A., Hollmann, T., Drill, E., Rademaker, J., Schoder, H., Inghirami, G., Weinstock, D. M., & Horwitz, S. M.
Venue
Blood
Published
2021-12-30
Volume
138
Issue
26
Pages
2828-2837
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3206514850
Cited by
190
References
2
FWCI
14.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. https://app.cochat.ai/papers/10.1182/blood.2021013379
The paper
Moskowitz, A. J., Ghione, P., Jacobsen, E., Ruan, J., Schatz, J. H., Noor, S., Myskowski, P., Vardhana, S., Ganesan, N., Hancock, H., Davey, T., Perez, L., Ryu, S., Santarosa, A., Dowd, J., Obadi, O., Pomerantz, L., Yi, N., Sohail, S., . . . Horwitz, S. M. (2021). A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. https://doi.org/10.1182/blood.2021013379

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.